Associations of coffee drinking with systemic immune and inflammatory markers

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 7, 2015, Pages 1052-1060

  Loftfield, Erikka ^a,b   Shiels, Meredith S ^a   Graubard, Barry I ^a   Katki, Hormuzd A ^a   Chaturvedi, Anil K ^a   Trabert, Britton ^a   Pinto, Ligia A ^c   Kemp, Troy J ^c   Shebl, Fatma M ^b,d   T mayne, Susan ^b,d   Wentzensen, Nicolas ^a   Purdue, Mark P ^e   Hildesheim, Allan ^f   Sinha, Rashmi ^a   Freedman, Neal D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b YALE UNIVERSITY   (United States)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d YALE CANCER CENTER   (United States)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; FIBROBLAST GROWTH FACTOR 2; FRACTALKINE; GAMMA INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MULTIVITAMIN; NONSTEROID ANTIINFLAMMATORY AGENT; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; BIOLOGICAL MARKER; COFFEE;

ADULT; AGED; ARTICLE; BODY MASS; CANCER SCREENING; CHRONIC DISEASE; COFFEE; COLORECTAL CANCER; DISEASE ASSOCIATION; DRINKING BEHAVIOR; DRUG USE; EDUCATION; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; FOOD INTAKE; FRUIT; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RED MEAT; SMOKING; VEGETABLE; WHITE MEAT; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEEDING BEHAVIOR; INFLAMMATION; INNATE IMMUNITY; MULTICENTER STUDY; NEOPLASMS; ODDS RATIO; PREVALENCE; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

AGED; BIOMARKERS; COFFEE; CROSS-SECTIONAL STUDIES; FEEDING BEHAVIOR; FEMALE; HUMANS; IMMUNITY, INNATE; INFLAMMATION; MALE; MIDDLE AGED; NEOPLASMS; ODDS RATIO; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84941766809     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0038-T     Document Type: Article

References (54)

1. National Coffee Association. National Coffee Drinking Trends. New York, NY: National Coffee Association; 2014. (Market research infographic).
2. Je Y, Giovannucci E. Coffee consumption and total mortality: A metaanalysis of twenty prospective cohort studies. Br J Nutr 2014;111: 1162-73.
3. Crippa A, Discacciati A, Larsson SC, Wolk A, Orsini N. Coffee consumption and mortality from all causes, cardiovascular disease, and cancer: A doseresponse meta-analysis. Am J Epidemiol 2014;180:763-75.
4. Freedman ND, Park Y, Abnet CC, Hollenbeck AR, Sinha R. Association of coffee drinking with total and cause-specific mortality. N Engl J Med 2012;366:1891-904.
5. Je Y, Giovannucci E. Coffee consumption and risk of endometrial cancer: findings from a large up-to-date meta-analysis. Int J Cancer 2012;131: 1700-10.
6. Galeone C, Turati F, La Vecchia C, Tavani A. Coffee consumption and risk of colorectal cancer: A meta-analysis of case-control studies. Cancer Causes Control 2010;21:1949-59.
7. Sinha R, Cross AJ, Daniel CR, Graubard BI, Wu JW, Hollenbeck AR, et al. Caffeinated and decaffeinated coffee and tea intakes and risk of colorectal cancer in a large prospective study. Am J Clin Nutr 2012;96: 374-81.
8. Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: A meta-analysis. BMC Gastroenterol 2013; 13:34.
9. Discacciati A, Orsini N, Wolk A. Coffee consumption and risk of nonaggressive, aggressive and fatal prostate cancer-a dose-response meta-analysis. Ann Oncol 2014;25:584-91.
10. Huxley R, Lee CM, Barzi F, Timmermeister L, Czernichow S, Perkovic V, et al. Coffee, decaffeinated coffee, and tea consumption in relation to incident type 2 diabetes mellitus: A systematic review with meta-analysis. Arch Intern Med 2009;169:2053-63.
11. Torres DM, Harrison SA. Is it time to write a prescription for coffee? Coffee and liver disease. Gastroenterology 2013;144:670-2.
12. Akash MS, Rehman K, Chen S. Effects of coffee on type 2 diabetes mellitus. Nutrition 2014;30:755-63.
13. Arnlov J, Vessby B, Riserus U. Coffee consumption and insulin sensitivity. JAMA 2004;291:1199-201.
14. Wu T, Willett WC, Hankinson SE, Giovannucci E. Caffeinated coffee, decaffeinated coffee, and caffeine in relation to plasma C-peptide levels, a marker of insulin secretion, in U.S. women. Diabetes Care 2005;28: 1390-6.
15. Lecoultre V, Carrel G, Egli L, Binnert C, Boss A, MacMillan EL, et al. Coffee consumption attenuates short-term fructose-induced liver insulin resistance in healthy men. Am J Clin Nutr 2014;99:268-75.
16. Lopez-Garcia E, van Dam RM, Qi L, Hu FB. Coffee consumption and markers of inflammation and endothelial dysfunction in healthy and diabetic women. Am J Clin Nutr 2006;84:888-93.
17. Kempf K, Herder C, Erlund I, Kolb H, Martin S, Carstensen M, et al. Effects of coffee consumption on subclinical inflammation and other risk factors for type 2 diabetes: A clinical trial. Am J Clin Nutr 2010;91:950-7.
18. Williams CJ, Fargnoli JL, Hwang JJ, van Dam RM, Blackburn GL, Hu FB, et al. Coffee consumption is associated with higher plasma adiponectin concentrations in women with or without type 2 diabetes: A prospective cohort study. Diabetes Care 2008;31:504-7.
19. Jacobs S, Kroger J, Floegel A, Boeing H, Drogan D, Pischon T, et al. Evaluation of various biomarkers as potentialmediators of the association between coffee consumption and incident type 2 diabetes in the EPICPotsdam Study. Am J Clin Nutr 2014;100:891-900.
20. Yamashita K, Yatsuya H, Muramatsu T, Toyoshima H, Murohara T, Tamakoshi K. Association of coffee consumption with serum adiponectin, leptin, inflammation and metabolic markers in Japanese workers: A cross-sectional study. Nutr Diabetes 2012;2:e33.
21. Correa TA, Rogero MM, Mioto BM, Tarasoutchi D, Tuda VL, Cesar LA, et al. Paper-filtered coffee increases cholesterol and inflammation biomarkers independent of roasting degree: A clinical trial. Nutrition 2013;29:977-81.
22. Tangney CC, Rasmussen HE. Polyphenols, inflammation, and cardiovascular disease. Curr Atheroscler Rep 2013;15:324.
23. Zampelas A, Panagiotakos DB, Pitsavos C, Chrysohoou C, Stefanadis C. Associations between coffee consumption and inflammatory markers in healthy persons: The ATTICA study. Am J Clin Nutr 2004;80:862-7.
24. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S-309S.
25. Hayes RB, Sigurdson A, Moore L, Peters U, Huang WY, Pinsky P, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res 2005;592:147-54.
26. Shiels MS, Pfeiffer RM, Hildesheim A, Engels EA, Kemp TJ, Park JH, et al. Circulating inflammation markers and prospective risk for lung cancer. J Natl Cancer Inst 2013;105:1871-80.
27. Trabert B, Pinto L, Hartge P, Kemp T, Black A, Sherman ME, et al. Prediagnostic serum levels of inflammationmarkers and risk of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol 2014;135:297-304.
28. Purdue MP, Hofmann JN, Kemp TJ, Chaturvedi AK, LanQ, Park JH, et al. A prospective study of 67 serum immune and inflammationmarkers and risk of non-Hodgkin lymphoma. Blood 2013;122:951-7.
29. Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, et al. Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst 2014;106 pii: dju294.
30. Chaturvedi AK, Kemp TJ, Pfeiffer RM, Biancotto A, Williams M, Munuo S, et al. Evaluation of multiplexed cytokine and inflammation marker measurements: A methodologic study. Cancer Epidemiol Biomarkers Prev 2011;20:1902-11.
31. Willett WC, Sampson L, Stampfer MJ, Rosner B, Bain C, Witschi J, et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am J Epidemiol 1985;122:51-65.
32. Block G, Hartman AM, Dresser CM, Carroll MD, Gannon J, Gardner L. A data-based approach to diet questionnaire design and testing. Am J Epidemiol 1986;124:453-69.
33. Salvini S, Hunter DJ, Sampson L, Stampfer MJ, Colditz GA, Rosner B, et al. Food-based validation of a dietary questionnaire: The effects of week-to-week variation in food consumption. Int J Epidemiol 1989; 18:858-67.
34. Feskanich D, Rimm EB, Giovannucci EL, Colditz GA, Stampfer MJ, Litin LB, et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency questionnaire. J Am Diet Assoc 1993; 93:790-6.
35. U.S. Department of Agriculture. Design and Operation: The Continuing Survey of Food Intakes by Individuals and the Diet and Health Knowledge Survey, 1994-96. Washington, DC: Agricultural Research Service, U.S. Department of Agriculture; 1997. (Nationwide Food Surveys Report no. 96-1).
36. Glickman ME, Rao SR, Schultz MR. False discovery rate control is a recommended alternative to Bonferroni-type adjustments in health studies. J Clin Epidemiol 2014;67:850-7.
37. Zock PL, Katan MB, Merkus MP, van Dusseldorp M, Harryvan JL. Effect of a lipid-rich fraction from boiled coffee on serum cholesterol. Lancet 1990; 335:1235-7.
38. Bonita JS, Mandarano M, Shuta D, Vinson J. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res 2007; 55:187-98.
39. Jick H, Miettinen OS, Neff RK, Shapiro S, Heinonen OP, Slone D. Coffee and myocardial infarction. N Engl J Med 1973;289:63-7.
40. Hennekens CH, Drolette ME, Jesse MJ, Davies JE, Hutchison GB. Coffeedrinking and death due to coronary heart-disease. New Engl J Med 1976;294:633-6.
41. Ding M, Bhupathiraju SN, Satija A, van Dam RM, Hu FB. Long-term coffee consumption and risk of cardiovascular disease: A systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation 2014;129:643-59.
42. Liu R, Guo X, Park Y, Huang X, Sinha R, Freedman ND, et al. Caffeine intake, smoking, and risk of Parkinson disease in men and women. Am J Epidemiol 2012;175:1200-7.
43. Vitaglione P, Morisco F, Mazzone G, Amoruso DC, Ribecco MT, Romano A, et al. Coffee reduces liver damage in a rat model of steatohepatitis: The underlying mechanisms and the role of polyphenols and melanoidins. Hepatology 2010;52:1652-61.
44. Tunnicliffe JM, Shearer J. Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators. Appl Physiol Nutr Metab 2008;33:1290-300.
45. Moon MK, Lee YJ, Kim JS, Kang DG, Lee HS. Effect of caffeic acid on tumor necrosis factor-alpha-induced vascular inflammation in human umbilical vein endothelial cells. Biol Pharm Bull 2009;32:1371-7.
46. Shechter M, Shalmon G, Scheinowitz M, Koren-Morag N, Feinberg MS, Harats D, et al. Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease. Am J Cardiol 2011;107:1255-61.
47. Hasko G, Cronstein B. Methylxanthines and inflammatory cells. Handb Exp Pharmacol 2011;200:457-68.
48. Chavez-Valdez R, Wills-Karp M, Ahlawat R, Cristofalo EA, Nathan A, Gauda EB. Caffeine modulates TNF-alpha production by cord blood monocytes: The role of adenosine receptors. Pediatr Res 2009;65:203-8.
49. Mustafa SJ, Nadeem A, Fan M, Zhong H, Belardinelli L, Zeng D. Effect of a specific and selective A(2B) adenosine receptor antagonist on adenosine agonist AMP and allergen-induced airway responsiveness and cellular influx in a mouse model of asthma. J Pharmacol Exp Ther 2007;320: 1246-51.
50. Shen T, Park YC, Kim SH, Lee J, Cho JY. Nuclear factor-kappa B/signal transducers and activators of transcription-1-mediated inflammatory responses in lipopolysaccharide-activated macrophages are amajor inhibitory target of kahweol, a coffee diterpene. Biol Pharm Bull 2010;33:1159-64.
51. Ahn SY, Cho CH, Park KG, Lee HJ, Lee S, Park SK, et al. Tumor necrosis factor-alpha induces fractalkine expression preferentially in arterial endothelial cells and mithramycin A suppresses TNF-alpha-induced fractalkine expression. Am J Pathol 2004;164:1663-72.
52. Bhavsar PK, Sukkar MB, Khorasani N, Lee KY, Chung KF. Glucocorticoid suppression of CX3CL1 (fractalkine) by reduced gene promoter recruitment of NF-kappaB. FASEB J 2008;22:1807-16.
53. Widmer U, Manogue KR, Cerami A, Sherry B. Genomic cloning and promoter analysis of macrophage inflammatory protein (MIP)-2, MIP-1 alpha, and MIP-1 beta, members of the chemokine superfamily of proinflammatory cytokines. J Immunol 1993;150:4996-5012.
54. Sica A, Dorman L, Viggiano V, Cippitelli M, Ghosh P, Rice N, et al. Interaction ofNF-kappaB and NFAT with the interferon-gamma promoter. J Biol Chem 1997;272:30412-20.